AIRS

AIRS (AI Robot Surgery) is a South Korean company founded in July 2020 by CEO Sanghyun Joung, specializing in the development of robotic systems for orthopedic surgery. Joung, who has been involved in surgical robot research and development for two decades, established the company to translate research into clinical applications, drawing on his experience with medical device licensing and clinical trials at the Medical Device Clinical Trial Center of Kyungpook National University Hospital.

The company's primary mission is to digitize and improve conventional fracture surgeries, which often suffer from challenges like potential bone mal-rotation, high manpower requirements, and radiation exposure for medical staff. AIRS addresses these issues with its core products: a Fracture Reduction Robot that uses a surgical robot and 3D navigation for precise alignment, and a Bone Tumor Surgery Robot that employs ultrasound imaging and AI for minimally invasive procedures. These systems aim to enhance surgical accuracy, improve safety by reducing radiation exposure, and increase operational efficiency by minimizing personnel and time.

Since its inception, AIRS has achieved several milestones. The company established its corporate research institute in November 2020 and received its medical device manufacturing license in December of the same year. It secured medical device approval for its fracture surgery robot from the KFDA in March 2023. The company has been successful in attracting funding, including a Series A round of $3.57 million (5 billion KRW) in March 2025, led by L&S Venture Capital with participation from other investors. This followed earlier investments in 2020 and 2021 from various firms and medical staff.

Keywords: robotic surgery, orthopedic surgery, fracture reduction, medtech, surgical navigation, AI in healthcare, bone tumor surgery, medical robotics, minimally invasive surgery, surgical robots, medical devices, long bone fractures, orthopedics, surgical technology, healthcare robotics, 3D imaging, clinical applications, venture capital, South Korea, Daegu